← Back to Search

Hormone Therapy

Anastrazole for Breast Cancer

Q: What is Anastrazole most often recommended to treat?

Anastrazole is often used to treat patients with the brca1 gene, but it can also be effective for other conditions like <a href="https://www.withpower.com/clinical-trials/breast-cancer">breast cancer</a>, pik3ca gene mutation, and malignant neoplasms.

Q: What is the current status of Anastrazole in regards to government regulation?

While there is some evidence to support the safety of Anastrazole, it receiving a score of 2 because there is no data currently supporting its efficacy.

Q: Are there any restrictions on how many people can enroll in this trial?

As of 5/17/2022, this trial is no longer active. It was initially posted on 5/1/2009. If you are interested in other trials, there are 2374 clinical trials for patients with malignant neoplasms and 190 trials for Anastrazole enrolling patients right now.

Q: Are people currently being recruited to participate in this trial?

Right now, this particular clinical trial is not looking for new patients to enroll. However, it was first posted on May 1st 2009 and most recently updated on May 17th 2022. If you are interested in other trials, 2374 studies involving malignant neoplasms are actively recruiting patients as well as 190 Anastrazole trials.

Q: What is the research history of Anastrazole?

Currently, 190 studies are underway for Anastrazole. Of these active investigations, 49 have reached Phase 3. Although a large majority of the trials originate in Pisa, Italy, there are 11840 locations worldwide conducting research on this medication.

Phase 2

Waitlist Available

Led By Qamar Khan, MD

Research Sponsored by University of Kansas Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 months

Awards & highlights

Study Summary

This trial is testing if a combination of two drugs is more effective and has fewer side effects than current treatments for early-stage hormone receptor positive breast cancer.

Eligible Conditions

Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pathologic Complete Response (PCR) Rate

Side effects data

From 2018 Phase 4 trial • 23 Patients • NCT02959853

Hospital admission

shoulder pain

heel pain

uncontrolled DM

100%

80%

60%

40%

20%

Study treatment Arm

Weight Loss

Aromatase Inhibitor (Anastrazole) Plus Weight Loss

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arimidex + FaslodexExperimental Treatment2 Interventions

Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks. On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fulvestrant

2011

Completed Phase 3

~3690

Anastrazole

2009

Completed Phase 4

~270

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor

461 Previous Clinical Trials

169,115 Total Patients Enrolled

23 Trials studying Breast Cancer

4,510 Patients Enrolled for Breast Cancer

AstraZenecaIndustry Sponsor

4,259 Previous Clinical Trials

288,593,860 Total Patients Enrolled

174 Trials studying Breast Cancer

1,246,339 Patients Enrolled for Breast Cancer

Qamar Khan, MDPrincipal InvestigatorUniversity of Kansas Medical Center

6 Previous Clinical Trials

976 Total Patients Enrolled

4 Trials studying Breast Cancer

853 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Anastrazole most often recommended to treat?

"Anastrazole is often used to treat patients with the brca1 gene, but it can also be effective for other conditions like breast cancer, pik3ca gene mutation, and malignant neoplasms."

Answered by AI

What is the current status of Anastrazole in regards to government regulation?

"While there is some evidence to support the safety of Anastrazole, it receiving a score of 2 because there is no data currently supporting its efficacy."

Answered by AI

Are there any restrictions on how many people can enroll in this trial?

"As of 5/17/2022, this trial is no longer active. It was initially posted on 5/1/2009. If you are interested in other trials, there are 2374 clinical trials for patients with malignant neoplasms and 190 trials for Anastrazole enrolling patients right now."

Answered by AI

Are people currently being recruited to participate in this trial?

"Right now, this particular clinical trial is not looking for new patients to enroll. However, it was first posted on May 1st 2009 and most recently updated on May 17th 2022. If you are interested in other trials, 2374 studies involving malignant neoplasms are actively recruiting patients as well as 190 Anastrazole trials."

Answered by AI

What is the research history of Anastrazole?

"Currently, 190 studies are underway for Anastrazole. Of these active investigations, 49 have reached Phase 3. Although a large majority of the trials originate in Pisa, Italy, there are 11840 locations worldwide conducting research on this medication."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

2009. "Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00921115.